* Core Laboratories NV CLB.N CLB is expected to show a
rise in
quarterly revenue when it reports results on February 1.
* The Amstelveen Noord-holland-based company is expected to
report a 4.2% increase in revenue to $130.338 million from
$125.14 million a year ago, according to the mean estimate from
5 analysts, based on Refinitiv data. The company's guidance on
October 26 2022, for the period ended December 31, was for
revenue between $126.00 million and $131.00 million.
* Refinitiv's mean analyst estimate for Core Laboratories
NV is
for earnings of 20 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
NV is $21, below its last closing price of $24.88.
The company's guidance on October 26 2022 for the period ended
December 31 was for Earnings before Interest and Taxes between
USD13 million and USD15 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.15 0.15 0.18 Beat 20.3
Jun. 30 2022 0.12 0.14 0.12 Missed -12
Mar. 31 2022 0.07 0.09 0.08 Missed -11.6
Dec. 31 2021 0.20 0.20 0.20 Met -0.4
Sep. 0.18 0.19 0.18 Missed -3.8
30 2021
Jun. 30 2021 0.19 0.19 0.18 Missed -6.2
Mar. 31 2021 0.12 0.13 0.15 Beat 15
Dec. 31 2020 0.15 0.15 0.18 Beat 16.5
This summary was machine generated January 30 at 22:26 GMT. All
figures in US dollars unless otherwise stated